Person:
Herrero Vanrell, María Del Rocío

Profile Picture
First Name
María Del Rocío
Last Name
Herrero Vanrell
URI
https://hdl.handle.net/20.500.14352/77475
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Farmacia
Department
Farmacia Galénica y Tecnología Alimentaria
Area
Farmacia y Tecnología Farmaceútica
Identifiers
UCM identifierORCIDScopus Author IDWeb of Science ResearcherIDDialnet IDGoogle Scholar ID

Filters

2017 - 201912020 - 20221
Reset filters

Settings

Author: Andrés Guerrero, Vanesa × Subject: 617.7-007.681 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
    (Advances in Therapy, 2017) Andrés Guerrero, Vanesa; Perucho González, Lucía; García Feijoo, Julián; Morales Fernández, Laura; Sáenz Francés, Federico; Herrero Vanrell, María Del Rocío; Pablo Júlvez, Luis; Polo Llorens, Vicente; Martínez De La Casa Fernández-Borrella, José María; Konstas, Anastasios Georgios P.
    The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
  • Thumbnail Image
    Item
    Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment
    (Pharmaceutics, 2022) González-Cela Casamayor, Miriam Ana; López Cano, José Javier; Bravo Osuna, Irene; Andrés Guerrero, Vanesa; Vicario De La Torre, Marta; Guzmán Navarro, Manuel; Benítez Del Castillo Sánchez, José Manuel; Herrero Vanrell, María Del Rocío; Molina Martínez, Irene Teresa
    Glaucoma is a group of chronic irreversible neuropathies that affect the retina and the optic nerve. It is considered one of the leading causes of blindness in the world. Although it can be due to various causes, the most important modifiable risk factor is the elevated intraocular pressure (IOP). In this case, the treatment of choice consists of instilling antihypertensive formulations on the ocular surface. The chronicity of the pathology, together with the low bioavailability of the drugs that are applied on the ocular surface, make it necessary to instill the formulations very frequently, which is associated, in many cases, with the appearance of dry eye disease (DED). The objective of this work is the design of topical ocular formulations capable of treating glaucoma and, at the same time, preventing DED. For this, two liposome formulations, loaded with brimonidine or with travoprost, were Tadeveloped using synthetic phospholipids and enriched by the addition of compounds with osmoprotective activity. The proposed formulations not only presented physicochemical characteristics (size, pH, osmolarity, surface tension, and viscosity) and encapsulation efficiency values (EE% of 24.78% and ≥99.01% for brimonidine and travoprost, respectively) suitable for ocular surface administration, but also showed good tolerance in human corneal and conjunctival cell cultures, as well as an in vitro osmoprotective activity. The hypotensive effect of both liposomal formulations was evaluated in normotensive albino New Zealand rabbits, showing a faster and longer lasting reduction of intraocular pressure in comparison to the corresponding commercialized products used as control. According to these results, the hypotensive liposomal formulations combined with osmoprotective agents would result in a very promising platform for the treatment of glaucoma and the simultaneous protection of the ocular surface.